Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

JAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and cancers added to its label in 2019. Now, a study designed to prove its safety ...

Pfizer has received approval from the US FDA for its rheumatoid arthritis (RA) drug, Xeljanz, which is the first approved RA treatment in a new class of medicines known as Janus kinase inhibitors ...

Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased ...

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific O ...

Some 60% of symptomatic ESID patients had received systemic corticosteroids; smaller proportions were given conventional disease-modifying antirheumatic drugs (DMARDs) such as azathioprine ...

The company faces a patent cliff over the next few years as multiple drugs including Eliquid, Ibrance, Xeljanz, and Xtandi lose exclusivity. However, I think this big pharma stock is a great pick ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...